The valuation is not my own guess and I'm not sure what was calculated or weighted to come up with that.
As far as cancer is concerned, it's not about whether or not there's potential. Mechanism with receptor has already shown a potential correlation....though that correlation is not the same as causation. Just because there is potential for it to work on certain cancers in only "some people" with the specific receptors, does not unfortunately provide justification for its use in cancer metastasis. And please remember the latter part of that, as the metastasis inhibition which is a potential, is not the same as apoptosis which is necessary for remission.
Delaying or limiting cancer metastasis is great if in stage 1 or 2. That can be the difference between life and death. The reason why this drug becomes less important in stopping metastasis in stage 3 and 4 is because the cancer has already expanded outside the target organ by that point, and into the lymph nodes, where it's then redistributed throughout other areas of the body attacking those respective organs. When at this point in some stage 3 and stage 4's, stopping metastasis will not help with increasing lifespan or allow for remission. The patient will require long spans of chemotherapy, combined with surgical removals. The intensity required to kill all the previously metastasized cancer cells would be too vast. This would provide some, but very little patient benefit. Cytodyn is looking at the cancer aspect wrong and incorrectly focusing on a higher stage of cancer because the public wants to hear about drugs that positively alter someone's life in a stage 3/4 cancer. Whereas, most people would be less excited to hear about a drug that successfully inhibits or prevents metastasis at a very early stage. It's really market perception and Cydy is doing trials based on that and the fact that they are needing data results more quickly which would occur with a stage 3/4 cancers and could be years in a lower stage. So even if Leronlimab could be successful in cancer therapy, they are basically shooting themselves in the foot by focusing on a more severe stage. I'm a believer in Cydy, but they should be focusing on a licensing offer that will be received rather than trying to sell a potential investor on "cancer hopes" when their interest is only in HIV.
As far as cancer is concerned, it's not about whether or not there's potential. Mechanism with receptor has already shown a potential correlation....though that correlation is not the same as causation. Just because there is potential for it to work on certain cancers in only "some people" with the specific receptors, does not unfortunately provide justification for its use in cancer metastasis. And please remember the latter part of that, as the metastasis inhibition which is a potential, is not the same as apoptosis which is necessary for remission.
Delaying or limiting cancer metastasis is great if in stage 1 or 2. That can be the difference between life and death. The reason why this drug becomes less important in stopping metastasis in stage 3 and 4 is because the cancer has already expanded outside the target organ by that point, and into the lymph nodes, where it's then redistributed throughout other areas of the body attacking those respective organs. When at this point in some stage 3 and stage 4's, stopping metastasis will not help with increasing lifespan or allow for remission. The patient will require long spans of chemotherapy, combined with surgical removals. The intensity required to kill all the previously metastasized cancer cells would be too vast. This would provide some, but very little patient benefit. Cytodyn is looking at the cancer aspect wrong and incorrectly focusing on a higher stage of cancer because the public wants to hear about drugs that positively alter someone's life in a stage 3/4 cancer. Whereas, most people would be less excited to hear about a drug that successfully inhibits or prevents metastasis at a very early stage. It's really market perception and Cydy is doing trials based on that and the fact that they are needing data results more quickly which would occur with a stage 3/4 cancers and could be years in a lower stage. So even if Leronlimab could be successful in cancer therapy, they are basically shooting themselves in the foot by focusing on a more severe stage. I'm a believer in Cydy, but they should be focusing on a licensing offer that will be received rather than trying to sell a potential investor on "cancer hopes" when their interest is only in HIV.
1
1
